Recent reports from 46brooklyn Research and their consulting arm 3 Axis Advisors have used publicly available drug pricing data, and when available data on prescription claims from independent pharmacies, in an attempt to identify proxies to highlight the differences between what the plan sponsor reimburses the pharmacy benefit manager (PBM) for a prescription versus what the PBM reimburses the pharmacy, otherwise known as “spread.”
Visante examined the data sources, methodologies, and conclusions in recent 46brooklyn reports for validity, reliability and/or potential sources of error. Visante found that 46brooklyn’s data sources, methodology and conclusions suffer from a number of flaws.
